FGFR-altered urothelial carcinoma in the EV–pembrolizumab era: Rationale and emerging data for upfront triplet strategies

Critical Reviews in Oncology/Hematology · Elsevier

Аннотация

Publication date: December 2026 Source: Critical Reviews in Oncology/Hematology, Volume 228 Author(s): Claudia Maria Ascione, Raffaella Congi, Stella Feliciello, Carmine Caso, Felice Crocetto, Ciro Imbimbo, Alberto Servetto, Fabrizio Di Costanzo, Roberto Bianco, Daniela Esposito, Luigi Formisano

Читать у издателя →

Похожие статьи